New! 🌿 Regulatory Timeline

In November 2025, Congress fundamentally redefined what counts as “hemp” at the federal level by passing a spending bill that retains the 0.3% Δ9-THC by dry weight definition for hemp cultivation, and adds a new, ultra-strict potency cap for finished products:

No more than 0.4 mg Total THC per container for any hemp-derived consumer product. 

The law also bans synthetic and semi-synthetic cannabinoids and significantly tightens control over intoxicating hemp derivatives (like Delta-8, THCP, and high-THCA “hemp” flower).

This is a direct response to the explosion of intoxicating hemp products created after the 2018 Farm Bill.

⸻

Federal Farm Bill History: How We Got Here

2014 Farm Bill — Pilot Programs

The Agricultural Act of 2014 launched state hemp research programs and opened the door to controlled hemp cultivation.

2018 Farm Bill — The Hemp Boom and the Loophole

The 2018 Farm Bill legalized hemp nationwide, defining it as:

Cannabis sativa L. with ≤ 0.3% Δ9-THC by dry weight.

It focused on the plant, not the finished product. That gap allowed manufacturers to:

Start with low-THC hemp biomass

Concentrate cannabinoids

Create high-potency “hemp” edibles, drinks, vapes, and smokables that were technically legal on paper but functionally equivalent to marijuana for the consumer.

This is the “loophole” Congress is now closing.

The 2025 Hemp Restructuring: The 0.4 mg Cap

The 2025 federal spending bill:

Redefines hemp products by imposing a 0.4 mg Total THC per container cap
Applies this limit to Total THC (Δ9-THC, THCA, and other THC isomers and analogs)
Eliminates the space for intoxicating hemp products outside licensed marijuana systems

Practically, this:

Bans 95%+ of existing intoxicating hemp products, including:
Delta-8 and THCP vapes
THC beverages
High-dose “hemp” gummies
Many Full Spectrum tinctures and even some topicals if they exceed 0.4 mg per jar

Total THC vs. Delta-Specific Definitions

Old model:

Focused on Δ9-THC only at the plant level (0.3% dry weight).
Ignored THCA and other isomers.

New model:

Focuses on Total THC in the finished product, in milligrams per container, not % by weight.
Includes THCA and other psychoactive analogs.
Bans synthetic or chemically converted cannabinoids (like many forms of Delta-8).

This shift from % THC in the plant to mg THC in the final product is what will erase most existing intoxicating hemp SKUs from the legal market.

Why the Loophole Opened — and Why It Closed

Why it opened:

Congress wanted to support hemp farmers (“rope, not dope”) but wrote a narrow Δ9-only, plant-weight rule.
Entrepreneurs saw an opportunity and built a $25–30 billion intoxicating hemp market with minimal licensing or taxation.

Why it closed:

Reports of children and adults ending up in ERs after consuming high-THC “hemp” products from gas stations and grocery stores.
Pressure from licensed marijuana operators and some alcohol interests who saw hemp drinks as competition.
Bipartisan concern that psychoactive cannabinoids were being sold with no age gating, no oversight, and confusing packaging.

The result: a quiet but seismic change — the 0.4 mg cap, effective November 2026, which many in the industry accurately describe as a de facto ban on intoxicating hemp.

Why Broad Spectrum Is the Safest Long-Term Model

Broad Spectrum CBD:

Keeps the beneficial components of the plant (CBD + minor cannabinoids + terpenes)
Removes all measurable THC, targeting non-detectable THC in finished products
Stays comfortably under the 0.4 mg cap
Is legal and safe to ship to all 50 states, including zero-tolerance states

This makes Broad Spectrum the logical endpoint of a maturing, compliant hemp wellness industry.

Safety, Drug Testing, and Legal Certainty

Key safety points:

Systemic CBD (oral/ingestible) can interact with common medications via CYP450 inhibition and may impact liver enzymes at higher doses.
This is one reason we stress responsible dosing, medical consultation, and prefer CBD for topical/local use when possible.
THC adds legal risk (Schedule I if over the cap), impairment risk, and drug testing risk, without clear added value in skincare.

Color Up’s Broad Spectrum and isolate strategy is explicitly designed to:

Keep customers safe
Keep practitioners compliant and protected
Keep distribution nationally viable under the strictest foreseeable rules

Conclusion: The Post-Loophole Era

The 0.4 mg Total THC cap marks the end of the intoxicating hemp era as we’ve known it. For brands who built their business on that loophole, this is an existential crisis. For brands like Color Up, who built on CBD, science, and compliance, it’s a confirmation.

The path forward is clear:

CBD-first
Broad Spectrum + isolate
Non-detectable THC
Topical efficacy + responsible systemic use
Rigorous testing, transparent COAs, and MoCRA/GMP manufacturing

Color Up will continue to:

Lead with truth over trend
Build products that are useful, legal, and safe
Serve as a safe harbor for B2B partners and consumers in this new, post-loophole hemp landscape.

⸻

This timeline outlines the critical regulatory milestones, risks, and required strategic responses for Color Up and our B2B partners (retailers, spas, and service providers). It serves as a clear guide to understanding the evolving legal landscape and ensuring proactive compliance.

Date/Period	Event/Legislation	Impact & Risk Assessment	Color Up Strategic Response
2012	Colorado Amendment 64 passes.	Established Colorado as the origin point for modern, regulated cannabis (both high-THC and hemp-derived).¹⁷	Founding Context: Colorado’s early, regulated market provided the necessary operational foundation for Color Up’s subsequent CDPHE-licensed manufacturing.¹¹
2018	Federal Farm Bill Enacted	Federally legalized "hemp" (defined as Cannabis sativa L. containing less than 0.3% Delta-9 THC on a dry weight basis) and guaranteed its commerce across state lines.²	Current Standard: This definition is the core legal basis for our full-spectrum products and interstate distribution.
2022	Modernization of Cosmetics Regulation Act (MoCRA)	New federal standards (GMP, Adverse Event Reporting) imposed on all cosmetic manufacturers, including CBD topicals.⁹	Mandatory Compliance: Our Denver facility must ensure seamless integration of MoCRA's federal safety standards with existing CDPHE licensing.
Jan 2023	FDA Defers CBD Regulation	FDA determined that existing food and supplement frameworks are inappropriate for CBD, deferring the creation of a permanent regulatory path to Congress.²⁹	Marketing Risk: We must strictly avoid all unapproved health, therapeutic, or structure/function claims, as enforcement continues.³¹
May 2024	DEA Rescheduling Proposal	DEA proposes moving high-THC cannabis from Schedule I to Schedule III. Hearing is later postponed.²¹	Market Opportunity: While indirect, this signals easing federal restrictions and could normalize the broader financial landscape (SAFER Banking).²⁷
Sept 2024	California State Regulations	California mandates zero detectable THC per serving for industrial hemp consumables and sets minimum purchase age at 21+.¹⁴	B2B Action Required: This requires partners in states like CA to stock CBD Isolate/Broad Spectrum consumable SKUs only. Full-spectrum consumables cannot be shipped to these restrictive states.
Late 2025 – Going into Effect Late 2026	Proposed 0.4mg Total THC Cap	Critical provision proposed in federal spending bills to limit finished hemp products to 0.4 milligrams of total THC per container.³	Existential Threat: This standard would render approximately 95% of our current full-spectrum consumable inventory federally illegal.⁷
Jan 2026	Tennessee Restriction Takes Effect	Tennessee is expected to shift to a more restrictive policy, only permitting the sale of CBD and CBG products, effectively banning other hemp-derived products.¹⁶	Proactive Inventory Management: Partners in permissive states must prepare for upcoming product restrictions and transition inventory away from soon-to-be-prohibited products.

Your cart is empty

Body Care